Background Dermatomyositis (DM) is an autoimmune disease affecting primarily the skin, muscle and lung. Dysregulations of cytokines and chemokines are commonly found in inflammatory disorders. Objectives To investigate the association between serum cytokines and chemokines and clinical severity, especially cutaneous lesions and interstitial lung disease (ILD) in patients with DM and clinically amyopathic DM (CADM). Methods Clinical features, laboratory findings and serum of 40 patients with DM or CADM were collected and analysed. Serum cytokines and chemokines were measured by enzyme-linked immunosorbent assay or cytometric bead array. A multiple unpaired t-test was performed to compare cytokines and chemokines in patients with DM and healthy controls. Correlations of serum cytokines and chemokines with disease severity were evaluated by Spearman's rank correlation test. Results Serum interferon (IFN)-b [r s = 0Á37, 95% confidence interval (CI) 0Á078-0Á62; P = 0Á019] and CXCL10 (r s = 0Á32, 95% CI to À0Á004 to 0Á57; P = 0Á045) were significantly correlated with the Cutaneous Dermatomyositis Disease Area and Severity Index activity score in the subset of patients with DM or CADM. Serum levels of interleukin (IL)-6, IL-10, IL-18 and IFN-b were significantly higher in the patients with acute/subacute interstitial pneumonia (A/SIP) than in the subset without A/SIP (P < 0Á05). IL-6 (r s = 0Á54, 95% CI 0Á27-0Á72; P < 0Á001) and IL-18 (r s = 0Á46, 95% CI 0Á21-0Á65; P = 0Á003) were significantly correlated with the serum level of anti-melanoma differentiation-associated protein 5 antibody. Conclusions Serum levels of IFN-b and CXCL10 may be useful biomarkers for assessing cutaneous disease activity in patients with DM and CADM. In addition, serum IL-6, IL-10, IL-18 and IFN-b were highly correlated with the occurrence of A/SIP. These cytokines may play a role in the pathogenesis of DM and CADM.
Summary
Background Dermatomyositis (DM) is an autoimmune disease affecting primarily the skin, muscle and lung. Dysregulations of cytokines and chemokines are commonly found in inflammatory disorders. Objectives To investigate the association between serum cytokines and chemokines and clinical severity, especially cutaneous lesions and interstitial lung disease (ILD) in patients with DM and clinically amyopathic DM (CADM). Methods Clinical features, laboratory findings and serum of 40 patients with DM or CADM were collected and analysed. Serum cytokines and chemokines were measured by enzyme-linked immunosorbent assay or cytometric bead array. A multiple unpaired t-test was performed to compare cytokines and chemokines in patients with DM and healthy controls. Correlations of serum cytokines and chemokines with disease severity were evaluated by Spearman's rank correlation test. Results Serum interferon (IFN)-b [r s = 0Á37, 95% confidence interval (CI) 0Á078-0Á62; P = 0Á019] and CXCL10 (r s = 0Á32, 95% CI to À0Á004 to 0Á57; P = 0Á045) were significantly correlated with the Cutaneous Dermatomyositis Disease Area and Severity Index activity score in the subset of patients with DM or CADM. Serum levels of interleukin (IL)-6, IL-10, IL-18 and IFN-b were significantly higher in the patients with acute/subacute interstitial pneumonia (A/SIP) than in the subset without A/SIP (P < 0Á05). IL-6 (r s = 0Á54, 95% CI 0Á27-0Á72; P < 0Á001) and IL-18 (r s = 0Á46, 95% CI 0Á21-0Á65; P = 0Á003) were significantly correlated with the serum level of anti-melanoma differentiation-associated protein 5 antibody. Conclusions Serum levels of IFN-b and CXCL10 may be useful biomarkers for assessing cutaneous disease activity in patients with DM and CADM. In addition, serum IL-6, IL-10, IL-18 and IFN-b were highly correlated with the occurrence of A/SIP. These cytokines may play a role in the pathogenesis of DM and CADM.
What's already known about this topic?
• The mechanism of cutaneous manifestations in dermatomyositis (DM) and clinically amyopathic DM (CADM) has not yet been elucidated.
• Cellular immunity, cytokine pathways, mechanical stress and sun exposure are possible contributors.
• The correlation between serum cytokines and chemokines and disease activity, including Cutaneous Dermatomyositis Disease Area and Severity Index and antimelanoma differentiation-associated protein (MDA)5 antibody, remains to be explored further.
What does this study add?
• Serum interleukin (IL)-6, IL-10, IL-18 and interferon (IFN)-b were highly correlated with the occurrence of acute/subacute interstitial pneumonia (A/SIP).
• Serum levels of IL-6 and IL-18 were significantly correlated with anti-MDA5 antibody, indicating that IL-6 and IL-18 may contribute to anti-MDA5 antibody-associated A/SIP.
• We report the correlation between cytokines and serum levels of anti-MDA5 antibody among Chinese patients with DM and CADM.
What is the translational message?
• Serum levels of IFN-b and CXCL10 may be useful biomarkers for assessing cutaneous disease activity in patients with DM and CADM.
The idiopathic inflammatory dermatomyopathies are a spectrum of clinical diseases with expression ranging from cutaneous-only disease to cutaneous and/or systemic disease. They include clinically amyopathic dermatomyositis (CADM), classical dermatomyositis (DM) and polymyositis/inclusion body myositis.
1,2 Dysregulations of cytokines and chemokines are commonly found in inflammatory disorders and are likely to participate in the pathogenesis of DM. It is generally accepted that cytokines and chemokines are essential players as regulators of leucocyte activation and migration. The cellular sources of cytokines and chemokines are immune cells, endothelial cells and muscle fibres. 3 In spite of numerous studies showing that cytokines and chemokines are involved and play a role in the pathogenesis of inflammatory myopathies, [4] [5] [6] [7] there is still a considerable lack of knowledge in this area. Cutaneous signs of DM are various in nature: some are pathognomonic or highly characteristic, and others are compatible with DM. 8 In the skin lesions of DM, activated CD4 + T helper lymphocytes are the principal infiltrating cells.
Although there is a slight T helper cell (Th)1 prevalence, clear polarization with neither Th1 nor Th2 has been found. CXCR3 positivity was detected in lesions of DM skin, in contrast to discoid lupus erythematosus and healthy controls, 9 indicating that cytokines, chemokines and their receptors could contribute to the occurrence of cutaneous lesions. Cytokines and chemokines could also be affected by the systemic inflammatory disorders, including myositis, dermatitis and interstitial lung disease (ILD) in DM. 10 Therefore, we investigated the association between cytokines and chemokines and clinical severity, especially cutaneous lesions and ILD.
Patients and methods

Patients and controls
The present study included 40 Clinical data including medical history and physical examination results were collected on admission (Table 1) . Exclusion criteria included treatment with systemic immunosuppressive therapy for two consecutive weeks or longer after the onset of skin lesions, and symptoms of myopathy and ILD. Patients were neither on antimalarials nor on topical therapy at the time serum was collected and skin diseases were evaluated. Sixteen healthy controls were also included for comparison of cytokines and chemokines against patients with DM and CADM. Informed consent from the study participants was obtained and the study was approved by the institutional review board.
Diagnosis of interstitial lung disease
The diagnosis of ILD was made according to the respiratory symptoms and the presence of bibasilar infiltrates on high- Assessment of the severity of skin diseases
Cutaneous disease activity was evaluated using the modified Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI). CDASI is a one-page instrument with three activity measures (erythema, scale and erosion/ulceration) and two damage measures (poikiloderma and calcinosis). The CDASI has a total score ranging from 0 to 132, which is divided into activity (0-100) and damage (0-32) subscores. The mean AE SD CDASI activity score for mild disease has been defined as 11Á4 AE 7Á0, with moderate 25Á6 AE 8Á9 and severe > 39Á4. [14] [15] [16] [17] Assessment of CDASI score was performed by two dermatologists (H.C. and M.C.).
Measurement of cytokines and chemokines
Serum cytokine concentrations were determined by flow cytometry of serum using the BD Cytometric Bead Array assay (BD Biosciences, San Diego, CA, U.S.A. 
Measurement of anti-melanoma differentiationassociated protein 5 antibody levels
The anti-melanoma differentiation-associated protein (MDA)5 antibody was detected by ELISA using a recombinant MDA5 protein. Recombinant MDA5 protein was expressed as a His-FLAG fusion protein using a mammalian expression system (pcDNA TM 3Á1/myc-His; Invitrogen, Carlsbad, CA, U.S.A.). Briefly, 96-well plates were coated with the purified recombinant MDA5 antigen (0Á5 lg mL À1 ) at room temperature overnight, before diluted patient serum (1 : 100) was added to each well. Absorbance at 450 nm was measured, and unit values (U mL À1 ) were calculated using a standard curve obtained from serial concentrations of serum containing a high titre of anti-MDA5 antibodies.
Statistical analysis
Comparisons of cytokines and chemokines between patients and healthy controls were performed using a multiple unpaired t-test. Correction for 14 comparisons was done using the Sidak-Bonferroni method, and the new a-level was 0Á0036 (0Á05/14). Cytokines and chemokines were compared between patients with and without A/SIP using the MannWhitney U-test. Correlations of serum cytokines and chemokines with disease severity, with 95% confidence intervals (CIs), were established by employing Spearman's rank correlation test. All data were analysed using SPSS 23Á0 software (IBM, Armonk, NY, U.S.A.) or GraphPad 6 software (GraphPad Software, La Jolla, CA, U.S.A.). A two-tailed P-value < 0Á05 was considered significant in all statistical analyses.
Results
Clinical characteristics
The cohort of patients with DM and CADM included 19 patients (13 male, six female) with classic DM and 21 (six male, 15 female) with CADM. The average age at onset was 56Á3 AE 12Á0 years. The mean disease duration was 7Á7 AE 11Á2 months. The patients with DM and CADM showed a high prevalence of ILD (28 of 40, 70%). The frequencies of A/SIP and chronic interstitial pneumonia were 33% (13 of 40) and 38% (15 of 40), respectively (Table 1) .
Serum cytokines and chemokines of patients with dermatomyositis and clinically amyopathic dermatomyositis
Serum levels of IL-6, IL-10, IL-18, IFN-b, CCL2, CXCL9 and CXCL10 were significantly higher in patients with DM or CADM than in healthy controls (P < 0Á05) ( Table 2 ). The differences of IL-10, IL-18, CXCL9 and CXCL10 between the two subsets of DM were also significant after using Sidak-Bonferroni correction. No significant differences in the levels of IL-2, IL-4, IL-8, IL-17A, tumour necrosis factor, IFN-c or CCL5 were detected between patients with DM or CADM and healthy controls (Table 2) .
Correlation between cytokine and chemokine levels and cutaneous disease activity
We next analysed the association between cytokine and chemokine levels and CDASI score. As shown in Table 3 , the levels of IFN-b (r s = 0Á37, 95% CI 0Á078-0Á62; P = 0Á019) and CXCL10 (r s = 0Á32, 95% CI À0Á004 to 0Á57; P = 0Á045) were significantly correlated with CDASI activity score. Scatter plots are shown in Figure S1 (see Supporting Information).
No correlation was found between cytokines or chemokines and CDASI damage score. Furthermore, patients with moderate-to-high disease activity (CDASI activity score > 20, n = 20) had significantly higher levels of IFN-b (11Á1 AE 13Á8 vs. 4Á6 AE 7Á3 pg mL
À1
, P = 0Á006) and CXCL10 (1627 AE 497 vs. 1169 AE 712 pg mL À1 ; P = 0Á035) than patients with mild-to-moderate disease activity (CDASI activity score ≤ 20, n = 20).
Correlation between cytokine and chemokine levels and interstitial lung disease
We also examined the correlation between cytokine and chemokine levels and ILD. In our cohort, the median (interquartile range) levels of IL- 3Á5 (5Á5) pg mL À1 ] were significantly higher in the patients with DM or CADM with A/SIP than in the subset without A/ SIP (P = 0Á009, 0Á039, 0Á025 and 0Á042, respectively) ( Fig. 1) . Levels of CCL2, CXCL9 and CXCL10 between the two subsets were not significantly different.
Concentrations of IL-6 (r s = 0Á54, 95% CI 0Á27-0Á72; P < 0Á001) and IL-18 (r s = 0Á46, 95% CI 0Á21-0Á65; P = 0Á003) were significantly correlated with serum levels of anti-MDA5 antibody. Levels of IL-6 (r s = À0Á46, 95% CI À0Á69 to À0Á16; P = 0Á006), IL-10 (r s = À0Á34, 95% CI À0Á57 to À0Á036; P = 0Á044) and CXCL10 (r s = À0Á38, 95% CI À0Á64 to À0Á061; P = 0Á023) were negatively correlated with serum C3 (Fig. 2 and Table S1 ; see Supporting Information).
Discussion
The mechanism of cutaneous manifestations in DM has not yet been elucidated. Cellular immunity, cytokine pathways, mechanical stress and sun exposure are possible contributors in the pathogenesis. 8, 9, 18, 19 In accordance with previous studies, 10, 20 we found serum levels of IL-10, IL-18 and CXCL10
to be significantly elevated in patients with DM and CADM compared with healthy controls. We also observed higher levels of serum CXCL9 in patients with DM and CADM, but the role of CXCL9 remains to be discovered. Differences of IL-6 and IFN-b, despite showing no significance after correction in this study, have been reported by other groups. [21] [22] [23] In our study, IFN-b and CXCL10 were significantly associated with CDASI activity score in patients with DM and CADM. CXCL10, also known as IFN-c-induced protein 10, is a ligand of CXCR3, which is preferentially expressed by Th1 cells. 24 Wenzel et al. showed that the type I IFN-associated recruitment of CXCR3 + lymphocytes plays an important role in lymphocyte skin homing in DM. 25 They hypothesized that lesional type I IFN signalling, induction of CXCL10 expression and recruitment of potentially autoreactive T cells via CXCL10-CXCR3 interaction are involved in the pathogenesis of DM skin lesions. We found positive correlations between serum levels of CXCL10 and IFN-b and CDASI activity score, which further supports the role of type I IFN signalling-induced CXCL10-CXCR3 interaction in skin disease in DM. Values are the mean AE SD in pg mL À1 . IL, interleukin; TNF, tumour necrosis factor; IFN, interferon. *P < 0Á05, **P < 0Á01, ***P < 0Á001. a Significant using the Sidak-Bonferroni method for correction. An unbiased gene array analysis of DM skin revealed closer correlation of IFN-inducible genes with transcript levels of IFN-b and IFN-c, compared with IFN-a transcript levels. 26 In our study, no correlation was found between serum IFN-c and CDASI activity score, while a significant correlation was found between serum IFN-b and CDASI activity score, suggesting that IFN-b drives DM skin disease activity, consistently with a previous study. 23 Furthermore, the elevation of serum CXCL10 and IFN-b was highly predictive of a CDASI activity threshold of 20 in the present study, while a threshold of 12 for CDASI activity score was reported before. 23 CDASI damage would not be expected to correlate with changes related to acute disease. ILD is common among patients with DM and CADM, and often correlates with a worse prognosis. 27 IL-6, IL-10 and IL-18 were associated with A/SIP in patients with DM and CADM. These results are consistent with those of previous studies. 10, 20, 28 Anti-MDA5 antibody has been detected in 20-50% of patients with DM and CADM in Asia; among them, up to 95% developed ILD. [29] [30] [31] [32] MDA5, the target antigen of this antibody, is a member of the RIG-like receptor family, which can recognize cytoplasmic viral double-stranded RNA and trigger consequent induction of type I interferon responses. 33 The role of anti-MDA5 antibody in the pathogenesis of DM remains poorly understood. We first reported the correlation between cytokines and serum levels of anti-MDA5 antibody among Chinese patients with DM and CADM. Serum levels of IL-6 and IL-18 were significantly correlated with anti-MDA5 antibody, indicating that the pathophysiology of anti-MDA5-associated ILD could be similar to that of macrophage activation syndrome (MAS). Central to the pathogenesis of MAS is cytokine storm, with markedly increased levels of numerous proinflammatory cytokines including IL-1, IL-6 and IL-18. 34 However, we did not obtain direct evidence of macrophage activation in anti-MDA5 antibody-positive patients.
Gono et al. have described that serum IL-18 is associated particularly with disease activity and ILD complication in DM. 20 The main cellular sources of IL-18 in muscle are macrophages and dendritic cells in DM. Activation of the IL-18-IL-18 receptor pathway may be a mechanism promoting endothelial inflammation and the subsequent migration of inflammatory cells within muscles. 20 In the present study, the serum level of IL-18 was significantly higher in patients with ulcerative Gottron papule or sign (data not shown) and in patients with A/SIP than in patients without those symptoms, which indicates that IL-18 may participate in vasculopathy. 35 Cao et al. have reported that anti-MDA5 antibody levels closely correlate with the severity of skin ulcerations and ILD. 36, 37 The striking vascular character of the skin phenotype in MDA5 antibody-positive patients and the rapidly progressive lung disease suggest that blood vessels are the primary target of the immune response, potentially initially targeted during viral infection, and driven later by the type I IFN pathway. 38 IL-18 and anti-MDA5 antibody are useful serum biomarkers of vasculopathy and are mutually connected in the mechanism of skin ulceration and ILD. In this context, the serum level of anti-MDA5 antibody was significantly correlated with IL-18. Our finding could be of assistance in clarifying the pathogenesis of anti-MDA5 antibody-associated DM. Deviating from our expectation, no significant association was found between serum anti-MDA5 antibody and IFN-b, which remains to be investigated further in larger cohorts of patients. The bars show the median and interquartile range of patients with A/SIP (n = 13) and patients without A/SIP (n = 27). Statistical analysis was performed using the Mann-Whitney U-test. *P < 0Á05, **P < 0Á01.
IL-6, IL-10 and CXCL10 are significant contributors to ILD and skin disease in DM. 28 In our cohort, IL-6, IL-10 and CXCL10 were negatively correlated with serum C3. Activation of C3 is an early event leading to the formation of C3b, C3bNEO and membrane attack complexes, which are deposited on the endothelial cell wall of endomysial capillaries. Cytokines released by activated complement lead to the activation of a series of immune cells. 1, 39 Deposition of C5b-9
was detected in endomysial microvessels 40, 41 and in a high percentage of skin biopsy specimens of patients with DM. 42, 43 Whether membrane attack complexes attack microvessels in lung remains to be investigated further. Patients with active DM were reported to have a significantly higher baseline C3 uptake than patients with chronic DM and other noncomplement-mediated neuromuscular diseases. 39 The serum level of C3 could be a candidate indicator of the evolution of ILD. There are several limitations in this study. Firstly, the cohort was retrospectively examined. Future prospective studies with more subsets would be highly useful. Secondly, the expression of cytokines and their receptors in cutaneous lesions (not only serum) might provide new insights into the aetiology of skin disease.
In conclusion, serum levels of IFN-b and CXCL10 may be useful biomarkers for assessing cutaneous disease activity in DM and CADM. Serum IL-6, IL-10, IL-18 and IFN-b were highly correlated with the occurrence of A/SIP. In addition, serum levels of IL-6 and IL-18 significantly correlated with anti-MDA5 antibody, indicating that IL-6 and IL-18 may play a role in the development of anti-MDA5 antibody-associated ILD. These cytokines may contribute to the pathogenesis of DM and CADM.
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